atorvastatin

In this study, a total of 100 patients with AIS were included for the current analysis (n = 50 for combination therapy of evolocumab and atorvastatin, PI group, n = 50 for atorvastatin monotherapy, AT group). http://www.chictr.org.cn; Identifier: ChicTR2200059445. Date of registration: 29 April 2022.

Collectively, these findings suggest that atorvastatin may disrupt the 'CSDH cycle' by modulating critical inflammatory, angiogenic and fibrinolytic mechanisms, providing a scientific rationale for its therapeutic application in CSDH management. Further in vivo studies are warranted to validate these preliminary observations and to explore clinical translation to the clinic.

P3, N=400, Recruiting, Central South University | N=200 --> 400

P1/2, N=60, Completed, Minia University | Recruiting --> Completed | Trial completion date: Jun 2026 --> Oct 2025 | Trial primary completion date: Mar 2026 --> Jul 2025

P1, N=96, Recruiting, Onconic Therapeutics Inc.

P3, N=1652, Recruiting, Aarhus University Hospital | Not yet recruiting --> Recruiting

Leveraging the observed sensitivity of muscle cells to atorvastatin in clinical settings and utilizing untargeted metabolomic analysis of atorvastatin-treated RD rhabdomyosarcoma cells, we identified reduced levels of aminoadipic acid, an intermediate in lysine catabolism...However, we demonstrated that it is catabolically cleaved to p-nitroanilide, with this molecule driving the cytotoxic activity observed in our experiments. Although lysine metabolism was not fully suppressed by lysine-p-nitroanilide, these findings provide valuable insights for developing novel therapies for rhabdomyosarcoma.

Neurohormonal blockers, including ACE inhibitors, ARBs, and β-blockers, constitute the foundation of prevention, although their efficacy varies: combinations such as ACEi/ARB with βB yield mixed outcomes, whereas carvedilol offers antioxidant benefits beyond β-blockade. Sacubitril/valsartan (ARNI) has demonstrated improvements in global longitudinal strain and LVEF preservation in the SARAH trial, albeit with associated hypotension risks. Aldosterone antagonists show potential, with spironolactone preserving LVEF and diastolic function, though eplerenone has not shown significant effects. Statins present conflicting data; the STOP-CA trial supports atorvastatin for LVEF preservation, while the PREVENT and SPARE-HF trials found no benefit. Emerging evidence suggests sodium-glucose cotransporter-2 inhibitors (SGLT2i), such as dapagliflozin and empagliflozin, as promising agents, with preclinical and early clinical data indicating cardioprotection through metabolic modulation, anti-inflammatory effects, and reduced oxidative stress...Future efforts should prioritize personalized approaches, dynamic risk assessment (e.g., HFA-ICOS tool), and a paradigm shift from oxidative stress to cardiometabolic dysfunction. Multidisciplinary collaboration is essential to optimize oncological outcomes while minimizing CV toxicity, with SGLT2i representing a key frontier for validation in ongoing trials.

P=N/A, N=40, Not yet recruiting, Takeda

P2, N=54, Completed, Tanta University | Recruiting --> Completed | Trial completion date: Sep 2027 --> Jun 2025 | Trial primary completion date: Jun 2026 --> Jun 2025

P=N/A, N=3048, Completed, Yonsei University | Recruiting --> Completed